Abstract Search

ey0020.2-10 | Long-Acting Growth Hormone (LAGH) | ESPEYB20

2.10. Long-acting PEGylated growth hormone in children with idiopathic short stature

X Luo , S Zhao , Y Yang , G Dong , L Chen , P Li , F Luo , C Gong , Z Xu , X Xu , H Gong , H Du , L Hou , Y Zhong , Q Shi , X Chen , X Chen , L Xu , R Cheng , C Su , Y Ma , L Xu , L Zhang , H Lu

Brief summary: This randomized, multicenter, controlled, phase II study compared the effects of high-dose (HD) once-weekly PEGylated-recombinant human growth hormone (PEG-rhGH) to low-dose (LD) and to an untreated control group of children with idiopathic short stature (ISS) over a period of 52 weeks. PEG-rhGH was effective in increasing height gain in a dose dependent manner with both doses being well tolerated during the observation period.PEG-rhGH is ...

1 shares

ey0021.9-9 | Fertility Issues | ESPEYB21

9.9. Risk of adverse birth outcomes after adolescent and young adult cancer

C Anderson , CD Baggett , SM Engel , D Getahun , NT Cannizzaro , S Mitra , C Meernik , LM Moy , CA Laurent , X Zhou , L Xu , ML Kwan , WA Wood , B Luke , CR Chao , LH Kushi , HB Nichols

Brief Summary: This retrospective cohort study analysed risk ratios for preterm birth (<37 completed weeks), very preterm birth (<34 completed weeks), low birth weight (<2500 g), and small for gestational age (SGA, <10th percentile of weight for gestational age) in a large group of women diagnosed with adolescent and young adult (AYA, age 15-39 years) breast cancer, thyroid cancer, gynaecologic cancers, lymphoma, or melanoma.1648 post-can...

0 shares

ESPE Yearbook of Paediatric Endocrinology

2.10. Long-acting PEGylated growth hormone in children with idiopathic short stature

9.9. Risk of adverse birth outcomes after adolescent and young adult cancer

BiosciAbstracts